An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients With Open Angle Glaucoma or Ocular Hypertension
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
Inclusion Criteria:
Exclusion Criteria:
La Jolla, California 92093, United States
Crystal River, Florida 34429, United States
Chicago, Illinois 60607, United States
Chesterfield, Missouri 63017, United States
Newark, New Jersey 07103-2425, United States
Slingerlands, New York 12159, United States
Charlotte, North Carolina 28210, United States
Winston-Salem, North Carolina 27101, United States
Falls Church, Virginia 22046, United States
CABA, Buenos Aires 1122, Argentina
Campo Grande, Mato Grosso do Sul 79002-075, Brazil
Halifax, Nova Scotia B3H 2Y9, Canada
Bucaramanga, Santander Department 681004, Colombia
Düsseldorf, North Rhine-Westphalia 40212, Germany
Perugia, 06156, Italy
Gdansk, Pomeranian Voivodeship 80-809, Poland
Olsztyn, Warmian-Masurian Voivodeship 10-424, Poland
Novosibirsk, Novosibirsk Oblast 630071, Russia
Istanbul, 34899, Turkey (Türkiye)